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Advances in science and technology aimed at identifying the complete genetic makeup of microorganisms are ushering 
in a new era for controlling infectious threats.  By using genetic sequencing to examine infectious pathogens, these 
technologies are on the verge of revolutionizing our ability to diagnose infectious diseases, investigate and control 
outbreaks, understand transmission patterns, develop and target vaccines, and determine antimicrobial resistance—all 
with increased timeliness and accuracy and decreased costs.  Recent reports have highlighted early efforts on the use of 
whole-genome sequencing (WGS) technologies in investigating outbreaks of drug-resistant bacteria in hospitalized 
patients at the National Institutes of Health Clinical Center and in the United Kingdom (Box 1), an outbreak of foodborne 
disease in Europe, and an outbreak of tuberculosis in Canada.  Termed “genomic epidemiology,” this approach to 
infectious disease control was named one of the six “Areas to Watch in 2012” by the journal Science on the basis of its 
transformative potential in “determining quickly where newly emerging diseases come from, whether microbes are 
resistant to antibiotics, and how they are moving through a population.” 
A New Landscape for Combatting Infectious Diseases 
New opportunities bring new challenges 
Along with the many opportunities afforded by these “next-generation” 
sequencing technologies come new responsibilities and challenges for clinical 
and public health.  In particular, the availability and ease-of-use of WGS 
technology is rapidly changing the way that diseases are studied—providing a 
new level of detailed information to better understand how infections occur 
and are transmitted.   
The major benefit of genomic sequencing is its ability to rapidly generate 
massive amounts of data on a pathogen.  A key component in the usefulness 
of these technologies, however, is ensuring the availability of sufficient 
laboratory and computing infrastructure (i.e., “bioinformatics”) and highly 
skilled experts to manage, analyze, evaluate, and gain new information from 
(i.e., make sense of) these large amounts of biological data.   
Ensuring continued public health capacity at CDC 
The Centers for Disease Control and Prevention (CDC) is recognized and relied upon nationally and globally for its strong 
epidemiologic and laboratory expertise and capacity for controlling infectious diseases, with laboratory reference 
capability for virtually all human infections.  Ensuring that CDC can continue to meet its responsibilities is a critical public 
health priority.  Because of resource constraints, CDC has not been able to develop the bioinformatics capacity to keep 
pace with the rapidly growing field of molecular diagnostics.   
To better identify gaps and make recommendations for best use 
of Agency resources in meeting these challenges, CDC convened 
a panel of external experts in bioinformatics, informatics, and 
laboratory information technology in 2011 to review the status of 
this technology at CDC and its ability to meet programmatic 
needs.  Among their feedback was a clarion call for urgent action:   
CDC is known for its strong ability to accurately 
analyze and interpret disease surveillance data.  
However, the Agency runs the risk of going from 
outdated to obsolete and then to irrelevant without 
strong investments in the science of bioinformatics . . .   
CDC is requesting dedicated  
FY 2014 funding to develop 
and incorporate new molecular 
technologies and bioinformatics 
capacities into public health—
improving infectious disease 
control efforts by CDC and its 
public health partners.  CDC’s 
current capacities in these areas 
are not sufficient to meet the 
challenges of this rapidly 
evolving field, threatening the 
Agency’s ability to meet its 
public health mission.   
The expert panel recommended both short-term and long-term goals to meet 
the most urgent needs and opportunities and to ensure that CDC’s capacities in 
these areas become “sustainable resources for public health.”  CDC has 
worked to address several of the short-term goals, including developing a 
nascent bioinformatics program to provide initial support for evolving scientific 
needs.  Among its activities, this core group has worked with programs across 
CDC’s infectious disease laboratories to identify priorities and to strengthen 
collaborations with outside agencies and partners.   Examples of priority areas 
include the following: 
 Bioinformatics Program Development 
– Enhancing CDC’s bioinformatics expertise and infrastructures   
– Working with partners to establish bioinformatics training 
fellowships to meet future workforce needs 
 Next-Generation PulseNet (Box2) 
– Modernizing PulseNet to encompass whole genome 
sequencing technologies to improve our ability to detect  
and respond to foodborne disease outbreaks  
– Expanding the use of these new capacities to other CDC 
national infectious disease surveillance networks   
 The Research Grade Network 
– Establishing a separate information technology network for  
use by CDC laboratories and their public health partners 
– Ensuring broader access to and facilitating rapid exchange of 
laboratory and bioinformatics information and datasets  
 MicrobeNet 
– Creating a system of web-accessible, searchable databases 
containing detailed, reference information to characterize  
infectious pathogens 
– Ensuring near real-time analysis and feedback of information 
on submitted pathogens for CDC and its local, state, national, 
and international laboratory partners 
Now and into the future 
Molecular-based technologies represent an evolving and rapidly 
changing field.  While the potential for their use across a wide range of 
specialties continues to evolve, at present they are on a course to totally 
reshape the practices of microbiology and infectious disease control.  As 
the use of these technologies extends to more and more clinical and 
laboratory settings, it is critical for CDC to have the molecular tools and 
bioinformatics capacity to provide expertise and leadership in ensuring 
that the expanding use of these technologies translates into meaningful 
information to guide effective public health action.    
Advances in molecular-based 
technologies along with enhanced 
bioinformatics capacities generate  
a new level of  information on 
infectious pathogens that can be 
used to more accurately and rapidly  
 Diagnose infectious diseases 
 Investigate and control outbreaks 
 Understand transmission patterns 
 Determine antimicrobial 
resistance 
 Develop and target prevention 
measures, including vaccines 
It is critical for CDC to have the 
molecular tools and bioinformatics 
capacity to provide expertise and 
leadership in ensuring that the 
expanding use of  these technologies 
translates into effective information 
for guiding public health action.    
Genomic mapping of  
Legionella pneumophila serogroup 8  
Expanding molecular technologies and 
bioinformatics capacities at CDC 
More than 1 million healthcare-associated infections (HAIs) and 100,000 related deaths occur in the United States each year.  At any 
given time, approximately 1 in 20 patients receiving treatment in U.S. hospitals has an HAI.  In addition to their tremendous toll on 
human health, these largely preventable infections add billions of dollars to healthcare costs each year.  Although much progress 
towards reducing these infections has been made over the last several years, HAIs remain all too common.  Complicating control efforts 
is the increasing number of outbreaks that involve drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), 
Clostridium difficile, and even more difficult-to-treat, gram-negative bacterial infections such as Escherichia coli and Klebsiella 
pneumoniae.  These gram-negative infections are increasingly resistant to most available antibiotics and can also pass along genetic 
materials that enable other bacteria to become drug-resistant.  With new resistant strains being identified across a spectrum of 
healthcare-associated, foodborne, respiratory, STD, and other infections, advances in genomic sequencing can play a critical role in 
rapidly identifying these infections, tracking their spread, and improving control measures.   
A New Landscape for Combatting Infectious Diseases 
Advances in genomic 
sequencing can play a 
critical role in rapidly 
identifying HAIs and 
tracking their spread—
providing important 
information for improving 
control measures.  CDC’s  
extensive and highly 
successful infectious disease 
surveillance networks, 
involving clinical, 
laboratory, and public 
health partners across the 
nation and globally, are 
poised to leverage these 
technologies in new and 
exciting ways to improve 
public health. 
Box 1. New Approaches to Reducing Healthcare-Associated Infections 
and Detecting Antibiotic Resistance 
Whole-genome sequencing (WGS) technology has been used to investigate several outbreaks of 
drug-resistant HAIs.   For one investigation, researchers in the United Kingdom used whole-
genome sequencing to re-examine an outbreak of MRSA that had occurred earlier in a neonatal 
unit.  Because traditional methods of subtyping are not able to clearly identify related MRSA 
infections, the researchers looked to WGS to better define the infections and determine 
transmission linkages.  The data identified a cluster of associated infections as well as separate 
infections not linked to the outbreak.  Although this investigation was performed 
retrospectively, it highlighted the potential use of WGS in providing timely and highly accurate 
information to better guide patient care and to improve infection control.   
Another recent investigation involved the use of WGS to help investigate the spread of 
carbapenem-resistant  K. pneumoniae among patients at the National Institutes of Health Clinical 
Center, after introduction of the highly resistant infection from a  woman transferred to the 
center to participate in a clinical trial in 2011.  Despite intensive infection control efforts, 
including almost immediate isolation of the index patient, the bacteria began to appear in 
patients across other areas of the center.  Many of these individuals died—some from their 
underlying illness and others from the infection.  Again, current typing methods are not able to 
distinguish differences in K. pneumoniae, so it was unclear whether all the patients were 
infected with the same strain.  Medical staff reached to researchers at the National Human 
Genome Research Institute, who used  genomic sequencing to help determine how the infection 
spread. The sequencing showed that all of the cases likely originated from the index patient, 
with the infections transmitted from bacteria on at least two different sites on her body during 
at least three separate events—providing important information for changing and implementing 
new infection control measures.   
CDC has strong expertise in the areas of HAIs and antimicrobial resistance.  In fact, CDC’s leadership in reducing HAIs through 
targeted educational and infection control efforts; improved means of reporting and tracking infections and evaluating control 
efforts; and increased involvement of states in these prevention efforts has helped the nation achieve dramatic results in this area, 
with reductions of nearly 60% in the occurrence of certain types of healthcare-associated bloodstream infections.  CDC’s extensive 
and highly successful infectious disease surveillance networks have been developed over the years with clinical, laboratory, and 
public health partners across the nation and globally.  These surveillance platforms are poised to leverage  
WGS and other molecular technology advancements in new and exciting ways to improve public health. 
Use of  WGS in Investigating Outbreaks of  HAIs 
Leveraging Molecular Technologies to Advance Public Health 
Box 2. Expanding the Use of Molecular Technologies to Improve  
Food Safety:  Next-Generation PulseNet 
An estimated 48 million foodborne illnesses occur in the United States each year, resulting in 128,000 hospitalizations and 3,000 
deaths.  CDC tracks and investigates foodborne diseases in collaboration with state and local health departments and other partners, 
working to rapidly identify their sources and contain their spread.  Essential to these efforts is PulseNet, a network of state and local 
public health and food regulatory agency laboratories across the United States and internationally that work to identify similar cases 
of foodborne illnesses that might signal an outbreak.  Over the past 15 years, PulseNet has revolutionized our ability to detect clusters 
of foodborne illness, detecting hundreds of outbreaks, enabling faster and better responses, and leading to important improvements 
in food safety. 
PulseNet’s national network of more than 80 state and federal laboratories use 
pulsed-field gel electrophoresis (PFGE) to examine DNA patterns of bacterial 
infections—a technology that has been used for decades.  These  laboratories submit 
PFGE patterns from bacteria of persons with foodborne infections to a CDC database 
for rapid comparison of strains of organisms such as Escherichia coli O157:H7, 
Salmonella, Shigella, Listeria, and Campylobacter.  Each year, approximately 50,000 
DNA fingerprints are uploaded into the PulseNet database.  Today, this laboratory 
network tracks a cumulative database that represents nearly half a million bacterial 
isolates from food, the environment, and persons with foodborne illness.  In 
addition to allowing for real-time communication among CDC, state and local health 
departments, and international partners, PulseNet also helps food regulatory agencies 
identify areas needing additional food safety measures by linking bacteria causing 
illnesses in people to bacteria detected in food. 
Enabling Real-time Communication on Foodborne Illness 
Modernizing PulseNet to Meet the Demands of   
Next-Generation Sequencing Technologies 
Like many of our public health disease surveillance networks, PulseNet relies on 
isolates from culture-based testing methods, the long-held standard in testing of 
specimens from patients with foodborne and other infections.  However, more and 
more diagnostic tests that do not use culture are being developed and marketed for 
clinical use, including use by clinical laboratories in diagnosing foodborne infections.  
Because of their reduced costs, rapid turnaround times, and less labor-intensive 
methodology, these tests may soon replace culture-based tests, necessitating 
fundamental changes in our public health efforts to track and control infectious 
diseases.  Modernizing PulseNet to meet these challenges through new technologies 
and expanding laboratory capabilities is a priority for CDC.  The need for enhanced 
capacity extends beyond PulseNet, however, to other national surveillance systems 
such as the National Antimicrobial Resistance Monitoring System.  Fortunately, 
building the bioinformatics and laboratory infrastructure to support these new 
technologies for one surveillance system can serve as a platform for their use across 
other systems.   
Laboratories play an important 
role in stopping contaminated 
food from reaching the public. 
Ensuring that PulseNet and other 
national infectious disease 
surveillance systems incorporate 
the molecular and bioinformatics 
technologies that are reshaping 
the practices of microbiology and 
infectious disease control is a 
critical priority for CDC and 
public health.   
As the use of these next-generation sequencing technologies continues to expand, it is 
essential that CDC’s national surveillance systems and laboratory infrastructure encompass the 
technology to ensure that infectious disease surveillance efforts are standardized and to enable 
CDC and its public health partners to most accurately detect, respond, and implement actions to 
contain newly emerging and well- recognized infectious threats regardless of their source.     
 
